Immune System Key Ltd.
Immune System Key Ltd. (ISK) is a privately held company that was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary.
It is engaged in discovery and development of innovative treatments for malignant and autoimmune diseases with strong unmet needs. ISK’s assets are based on novel human secreted peptides, which were discovered by the founders. ISK’s lead compound is NerofeTM. NerofeTM was granted by the FDA with orphan drug status for AML treatment and currently is in phase IIa development stage. The company holds 3 worldwide patents on the molecule and applications.
LATEST NEWS
Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal
ISK is excited to report the official opening of its second FDA approved clinical trial in the US in patients with pancreatic cancer and metastatic colorectal cancer at Georgetown University in Washington, D.C.
IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track
Following FDA approval to open our trial at Georgetown University in Washington DC, we received final IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track
New Nerofe Formulation for treatment of Stage 4 squamous cell lung cancer
Using a new formulation of Nerofe, treating a patient with Stage 4 squamous cell lung cancer (positive for ST2), caused the complete disappearance of some tumors and a decrease in the size of other tumors. Increase in hepatic function.
New Nerofe Formulation for treatment of adenocarcinoma in the anus with metastasis in the peritoneum
Using a new formulation of Nerofe on a patient (positive for ST2) with adenocarcinoma in the anus and two metastasis in the peritoneum caused the complete disappearance of tumors.
ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC
ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC
Phase II update – A second patient (92 years old) had a strong reduction in blasts in the bone marrow
No side effects were recorded
